Case Presentation: 74-Year-Old Man With Relapsed/Refractory Follicular Lymphoma
Kami Maddocks, MD, presents the patient diagnosis and treatment history of a 74-year-old-man with relapsed/refractory follicular lymphoma.
Related Articles
Evaluating the Impact of Neoadjuvant Therapy in Localized Breast Cancer
Neoadjuvant chemotherapy’s effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.
FDA Considers Approval of TLX250-CDx in Kidney Cancer
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC…
MARIPOSA Trial Shows PFS Benefit With or Without CNS Disease in NSCLC
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small…
December II, 2024
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Advancing Trials for HER2+ Breast Cancer With Leptomeningeal Metastasis
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive breast cancer and leptomeningeal metastasis.
Understanding When to Choose Systemic Treatment for Desmoid Tumors
Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.
FDA Approves Tepylute in Breast and Ovarian Cancer
The FDA approved tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.
December II, 2024
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
I-SPY2.2: A Personalized Approach to Neoadjuvant Breast Cancer Treatment
Rebecca A. Shatsky, MD, discussed the I-SPY2.2 trial, its novel design, and its implications for the treatment of patients with breast cancer.
An Overview of the Current Treatment Landscape for R/R FL
A panelist discusses how managing relapsed/refractory follicular lymphoma (R/R FL) requires carefully weighing multiple factors including patient fitness, prior therapies, duration of response, symptoms, and…